ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,048.42
-0.46%
US Tech 100
17,178.00
0.69%
Dow Jones
38,085.80
-0.98%
Brent Oil
88.15
1.07%
Bitcoin
64,676.52
0.62%
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Celyad Oncology SA (CYAD) Quote

Celyad Oncology SA

Celyad Oncology SA (CYAD)

Celyad Oncology SA
0.47
0.00
(0.00%)
At close: April 25 4:00PM
Delayed by 15 minutes
0.47
0.00
( 0.00% )
After Hours: -
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.47
Bid
0.47
Ask
0.52
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
12.843M
Previous Close
0.47
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
41,429,000
Dividend Yield
-
PE Ratio
-1.52
Earnings Per Share (EPS)
-0.2
Revenue
102k
Net Profit
-8.45M

About Celyad Oncology SA

Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm h... Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.celyad.com
Headquarters
Wavre, Walloon Brabant, Bel
Founded
1970
Celyad Oncology SA is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CYAD. The last closing price for Celyad Oncology was $0.47. Over the last year, Celyad Oncology shares have traded in a share price range of $ 0.00 to $ 0.00.

Celyad Oncology currently has 41,429,000 shares outstanding. The market capitalization of Celyad Oncology is $12.84 million. Celyad Oncology has a price to earnings ratio (PE ratio) of -1.52.

CYAD Latest News

More News

Celyad Oncology publie ses résultats financiers pour l'année 2023 ainsi que les récents évènements marquants

Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (la “Société”), annonce aujourd'hui ses résultats financiers pour l'année 2023 au 31 décembre 2023 et présente une mise...

April 04 2024
Business Wire

Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights

Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the “Company”), today announces its financial results for the fiscal year 2023 ended December 31, 2023, and provides a...

April 04 2024
Business Wire

Celyad Oncology Announces Intention to Terminate SEC Reporting Obligations

Regulatory News: Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that it will voluntarily file a Form 15F with the United States Securities and Exchange...

February 08 2024
Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

January 17 2024
Edgar (US Regulatory)

Celyad Oncology fait le point sur les activités du quatrième trimestre 2023 et présente ses perspectives pour 2024

Trois piliers principaux pour libérer le potentiel des plateformes technologiques propriétaires et de la propriété intellectuelle : Une plateforme technologique exclusive sans édition de génome...

January 16 2024
Business Wire

Celyad Oncology Provides Fourth Quarter 2023 Business Update and 2024 Outlook

Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: A proprietary non-gene editing technology platform based on multiplexing of short hairpin...

January 16 2024
Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

December 21 2023
Edgar (US Regulatory)

Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC

(Article 14 §1 of the Law of 2 May 2007) Regulatory News: Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) today announces, in...

December 20 2023
Business Wire

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Regulatory News: Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces that 6,500,000 shares of CFIP CLYD (UK) Limited benefit from a double voting right as of...

December 15 2023
Business Wire

Celyad Oncology SA : Information relative au Nombre Total de Droits de Vote et d’Actions (Article 15 de la Loi du 2 Mai 2007)

Regulatory News: Celyad Oncology SA (Euronext : CYAD) (la « Société » ou « Celyad Oncology ») annonce en ce jour que 6.500.000 actions de CFIP CLYD (UK) Limited bénéficient d’un double droit de...

December 15 2023
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TVGNTevogen Bio Holdings Inc
$ 1.26
(48.24%)
246.4k
PEGYPineapple Energy Inc
$ 0.0715
(37.76%)
49.18M
ELWSEarlyworks Co Ltd
$ 0.925
(25.79%)
2.23M
COOTAustralian Oilseeds Holdings Ltd
$ 1.7397
(23.93%)
19.8k
GGLLDirexion Daily GOOGL Bull 2X ETF
$ 44.48
(23.49%)
199.36k
VINCVincerx Inc
$ 0.7489
(-16.48%)
361.31k
ACONAclarion Inc
$ 0.33
(-15.97%)
1.62M
ATXIAvenue Therapeutics Inc
$ 0.1002
(-14.36%)
504.24k
ISUNiSun Inc
$ 0.15
(-12.89%)
5M
GGLSDirexion Daily GOOGL
$ 13.52
(-12.09%)
212.23k
PEGYPineapple Energy Inc
$ 0.0715
(37.76%)
49.18M
GOOGLAlphabet Inc
$ 175.00
(12.18%)
11.45M
SQQQProShares UltraPro Short QQQ
$ 11.57
(-3.58%)
9.21M
INTCIntel Corporation
$ 32.30
(-8.00%)
7.86M
GOOGAlphabet Inc
$ 177.00
(12.06%)
5.91M

Discussion

View Full Feed
Chart Reader Chart Reader 1 minute ago
Thanks for the information. I like to follow up on anything I have written. I don't like to say things and not follow up on them. Hey, in life we all have to prove our words with actions and I did give a chart evaluation here, and if nothing else, I have to supply the results of that evaluation.
LWLG
sricket sricket 1 minute ago
Chameleons, change color in the same post.
IQST
SPORT19 SPORT19 2 minutes ago
Waiting for “New PKTX PR news”

LMFAO!

PKTX
getmoreshares getmoreshares 2 minutes ago
not much info was reported in the podcast-- asked for a summery-- I was cut-off from the interview
GRPS
janice shell janice shell 3 minutes ago
That is truly ridiculous. Your father was right. Most people's signatures are more or less illegible.
amod1222333 amod1222333 3 minutes ago
lol going dark, expert market, everyone involved in hiding....it's all part of a 5 year plan huh? Lol
WSRC
georgebailey georgebailey 4 minutes ago
Newman- I think the idea here is that nwbo cross licenses with Oncovir everywhere which I’ll call the master license.
BP that wants to combo their drug would take a license on the master for trials thru commercialization.
For GBM, we have the master license in place- Merck would still
CRL
StockInfo11 StockInfo11 4 minutes ago
BlackRock suggests that copper needs to hit $12,000 per ton, a 20% increase from its current high, to motivate investments in new mines⬇️
https://www.mining.com/web/blackrock-says-12000-copper-is-needed-to-incentivize-new-mines/

Recent exploration at PRIZ's Hot Breccia revealed
PMOMF
blownaccount9 blownaccount9 4 minutes ago
Didn’t seem to impact Freddie
FNMA
SPORT19 SPORT19 4 minutes ago
Lol…
PKTX
newmedman newmedman 4 minutes ago
I have two whole sets, maybe twenty knives but I don't use hardly any of them without rotating my stock. I have numerous butter knives also but that's not here or there.

I have sharpening stones that I will use sometimes but I have no idea why you need a knife that could slic
carolinatiger carolinatiger 4 minutes ago
Proof it's a scam or just say, in your OPINION.
IGPK
MJ19 MJ19 4 minutes ago
Any new info?
GRPS
amod1222333 amod1222333 4 minutes ago
time has told. These guys went dark, ran, and went expert market. There is no big mystery here.
WSRC
fuagf fuagf 4 minutes ago
Just wait until you elect me again ..

https://cdn.creators.com/214/369750/369750_image.jpg

.. this isn't new either ..

https://cdn.mos.cms.futurecdn.net/BRv4ZreGHeHhZTKwN33j2X-1024-80.jpg.webp
crowin crowin 5 minutes ago
Were you the one to paint the tape up at close today to show green?

More sells than buys again today!!

https://ih.advfn.com/stock-market/USOTC/intergrated-cannabis-sol-pk-IGPK/trades
IGPK
StockInfo11 StockInfo11 5 minutes ago
TMAS' La Blache Proj PEA forecasts a $6.6B NPV at 660K tons annual Titanium Dioxide production on a 14-year mine life. + TMAS.c's leaching technology reduces processing costs by up to 65% while reusing over 95% of reagents
https://temasresources.com/temas-files-preliminary-economic-assessment
TMASF
StockItOut StockItOut 5 minutes ago
Why would the audit show "stronger than expected numbers"? The audit is mainly to legitimize the company and its books. I expect Brookmount is reporting financials accurately as it does each quarter.
BMXI
carolinatiger carolinatiger 5 minutes ago
Guess you will be moving 9n then since you don't like it here? No reason to stay. Lol. Boom
IGPK
bjl bjl 5 minutes ago
https://twitter.com/agbagroup/status/1783628315527401830
AGBA
igotthemojo igotthemojo 5 minutes ago
“Nothing like numbers, wouldn't you say?”

The “numbers” were for the prior quarter…no one can invest in the past…the guidance the company gave is for times to get tougher for them to make a buck…the stock price is likely to reflect that, unless other good news comes out…
FCEL
Batman412 Batman412 6 minutes ago
Still not one 8k
TONR
Dubbie1 Dubbie1 6 minutes ago
You stole those shares, Glenn. I wish I had some extra cash to throw on this right now. Good job, brother!
LICH

Your Recent History

NASDAQ
CYAD
Celyad Oncology
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved